Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

A. J. Weickhardt; F. Foroudi; J. Xie; K. Kanojia; M. Sidhom; A. Pal; P. Grimison; A. Zhang; S. Ng; C. Tang; E. Hovey; C. Chen; G. Hruby; A. Guminski; M. Mcjannett; C. J. Conduit; N. Lawrentschuk; B. Tran; I. D. Davis; D. Hayne

doi:10.1016/j.annonc.2022.07.1817

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

A. J. Weickhardt, F. Foroudi, J. Xie, K. Kanojia, M. Sidhom, A. Pal, P. Grimison, A. Zhang, S. Ng, C. Tang, E. Hovey, C. Chen, G. Hruby, A. Guminski, M. Mcjannett, C. J. Conduit, N. Lawrentschuk, B. Tran, I. D. Davis, D. Hayne

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

5 Citations (Web of Science)

Original language	English
Pages (from-to)	S1332-S1332
Number of pages	1
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.07.1817
Publication status	Published - Sept 2022
Externally published	Yes
Event	2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France Duration: 9 Sept 2022 → 13 Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.07.1817

Cite this

Weickhardt, A. J., Foroudi, F., Xie, J., Kanojia, K., Sidhom, M., Pal, A., Grimison, P., Zhang, A., Ng, S., Tang, C., Hovey, E., Chen, C., Hruby, G., Guminski, A., Mcjannett, M., Conduit, C. J., Lawrentschuk, N., Tran, B., Davis, I. D., & Hayne, D. (2022). Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502). Annals of Oncology, 33(7), S1332-S1332. https://doi.org/10.1016/j.annonc.2022.07.1817

@article{d92ef08e45c04fe695de87bc87a85350,

title = "Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)",

author = "Weickhardt, {A. J.} and F. Foroudi and J. Xie and K. Kanojia and M. Sidhom and A. Pal and P. Grimison and A. Zhang and S. Ng and C. Tang and E. Hovey and C. Chen and G. Hruby and A. Guminski and M. Mcjannett and Conduit, {C. J.} and N. Lawrentschuk and B. Tran and Davis, {I. D.} and D. Hayne",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.07.1817",

language = "English",

volume = "33",

pages = "S1332--S1332",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

note = "2022 Annual Meeting of the European-Society-for-Medical-Oncology, ESMO 2022 ; Conference date: 09-09-2022 Through 13-09-2022",

}

Weickhardt, AJ, Foroudi, F, Xie, J, Kanojia, K, Sidhom, M, Pal, A, Grimison, P, Zhang, A, Ng, S, Tang, C, Hovey, E, Chen, C, Hruby, G, Guminski, A, Mcjannett, M, Conduit, CJ, Lawrentschuk, N, Tran, B, Davis, ID & Hayne, D 2022, 'Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)', Annals of Oncology, vol. 33, no. 7, pp. S1332-S1332. https://doi.org/10.1016/j.annonc.2022.07.1817

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502). / Weickhardt, A. J.; Foroudi, F.; Xie, J. et al.
In: Annals of Oncology, Vol. 33, No. 7, 09.2022, p. S1332-S1332.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer

T2 - 2022 Annual Meeting of the European-Society-for-Medical-Oncology

AU - Weickhardt, A. J.

AU - Foroudi, F.

AU - Xie, J.

AU - Kanojia, K.

AU - Sidhom, M.

AU - Pal, A.

AU - Grimison, P.

AU - Zhang, A.

AU - Ng, S.

AU - Tang, C.

AU - Hovey, E.

AU - Chen, C.

AU - Hruby, G.

AU - Guminski, A.

AU - Mcjannett, M.

AU - Conduit, C. J.

AU - Lawrentschuk, N.

AU - Tran, B.

AU - Davis, I. D.

AU - Hayne, D.

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000866211602289

U2 - 10.1016/j.annonc.2022.07.1817

DO - 10.1016/j.annonc.2022.07.1817

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1332-S1332

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

Y2 - 9 September 2022 through 13 September 2022

ER -

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

UN SDGs

Access to Document

Other files and links

Cite this